Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women’s healthcare, announced today that it started the Phase III clinical development program OASIS, which aims to evaluate the efficacy and ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...
WHIPPANY, N.J., April 14, 2015 -- Bayer HealthCare today announced the expansion of its global clinical development program for the investigational oncology compound copanlisib (BAY 80-6946), which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results